New target therapies in advanced pancreatic cancer.
The recent elucidation both of the mechanisms involved in pancreatic cancer carcinogenesis and the related molecular events, has led to several distinct therapeutic advances, including many novel target agents, such as monoclonal antibodies against EGFR, EGFR-tyrosine kinase inhibitors, monoclonal antibody against VEGF, farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, COX 2 inhibitors, and the development of gene therapy to target pancreatic cancer. This review highlights recent findings in the treatment of pancreatic cancer by using these novel therapeutic approaches.
Cascinu
S
S
Clinica di Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy. cascinu@yahoo.com
Verdecchia
L
L
Valeri
N
N
Berardi
R
R
Scartozzi
M
M
D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D018450:Disease Progression; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D018390:Gene Targeting; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D010190:Pancreatic Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D052246:Cyclooxygenase 2 Inhibitors; D016328:NF-kappa B; D011480:Protease Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051231:Farnesyltranstransferase; C512478:EGFR protein, human; D066246:ErbB Receptors; D045726:Metalloproteases